Sensus Blog

The future of skin cancer treatment is now. Stay ahead of the curve with our library of informational blogs.

April
27
2026

Basal Cell Carcinoma vs. Squamous Cell Carcinoma: What’s the Difference?

Melanoma and non-melanoma are two primary categories of skin cancer. Each presents different symptoms and treatment options. Within the non-melanoma skin cancer – sometimes referred to as NMSC – category, the two most common types…

March
06
2025

Sensus Healthcare to Showcase Commercial and Late-Stage Products at the American Academy of Dermatology Annual Meeting

Full line of SRT products along with innovative pre-commercial products including portable lesion detection and TransDermal Infusion to be featured in a brand-new, A.I.-focused environment at Booth #2451 BOCA RATON, Fla. – Sensus Healthcare, Inc….

March
04
2025

Sensus Healthcare Announces Publication of Study at Tri Service Military Hospital in Taiwan Demonstrating Efficacy of SRT-100® in Preventing Keloid Recurrence

BOCA RATON, Fla. – Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the publication of a study titled…

February
28
2025

The Evolution of Skin Cancer Treatment: How SRT-100 Vision is Changing the Game in Non-Invasive Skin Cancer Treatment

Skin cancer, particularly non-melanoma skin cancer (NMSC), is one of the most common cancers worldwide. Traditionally, treatments for NMSC have included surgery, radiation, and topical therapies. However, recent innovations have revolutionized the way we approach…

February
28
2025

Introducing the Fair Deal Agreement: Revolutionizing Dermatology Practices with Sensus Healthcare

At Sensus Healthcare, we are committed to advancing patient care and empowering dermatology practices with innovative solutions. One of our most exciting developments in 2024 is the launch of the Fair Deal Agreement, a program…

Archives
Archives

IN THE NEWS

CEO Joseph Sardano on Coding for Superficial Radiation Therapy